Clinical Trials Logo
  1. Home
  2. Drug Toxicity
  3. NCT06019520

Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity

Drug Toxicity Clinical Trial

Official title:
Role of N-Acetylcysteine for Prevention of Cisplatin-induced Nephrotoxicity

Clinical Trial Summary

Cisplatin is one of the first-line drugs used against many malignancies, such as lung cancer, head and neck cancer, esophageal cancer, gastric cancer, colorectal cancer, urothelial cancer, bladder cancer and testicular cancer. The usage of Cisplatin is limited by its severe nephrotoxicity, which particularly affects the proximal tubule epithelial cells (PTEC).Several studies suggest role of NAC in ameliorating Cisplatin induced nephrotoxicity, although definitive data is lacking. N-Acetylcysteine (NAC) is a thiol-containing antioxidant, which not only acts as a precursor of glutathione but also as a direct antioxidant .There are multiple postulated mechanisms for NAC's nephroprotection. NAC is a low-cost, easily available drug with a very good safety profile and therefore can be added as a support medication during treatment with cisplatin. The investigators plan to administer 1200 mg oral NAC 12 hours before chemotherapy and then daily at night for the subsequent 6 days, with an objective to ascertain its nephroprotective role in population receiving Cisplatin/-based chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06019520
Study type Interventional
Source Foundation University Islamabad
Contact
Status Active, not recruiting
Phase N/A
Start date August 9, 2023
Completion date March 9, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Recruiting NCT04696081 - Atrial Fibrillation in Active Cancer Patients
Active, not recruiting NCT03651778 - GHB Poisoning and Poisoning Induced by Others
Completed NCT04120233 - MW151-101: First-in-human Study of MW151 Phase 1
Recruiting NCT01965275 - High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs Phase 2
Completed NCT01614080 - Outcome of Patients Treated by iv Rt-PA for Cerebral Ischaemia According to the Ratio Sc-tPA/Tc-tPA N/A
Recruiting NCT04659343 - TDM for Optimized Outcome in Patients With mRCC.
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT01135680 - Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100 Phase 1
Completed NCT03947034 - Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)
Recruiting NCT03885388 - Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6 Phase 2/Phase 3
Completed NCT00491595 - Phase I Clinical Study of Soy Isoflavones in Healthy, Post-Menopausal Women Phase 1
Recruiting NCT03469063 - Impact of AferBio® on Quality of Life and Chemotherapy Toxicity in Lung Cancer Patients N/A
Not yet recruiting NCT04671589 - Antidote for Valproic Acid Toxicity: a New Indication for Meropenem Antibiotic. Phase 4
Completed NCT03280368 - Adherence and Coagulation Assays in Dabigatran-treated Patients With Atrial Fibrillation
Withdrawn NCT01374061 - Pre Hospital Evaluation of Video Laryngoscopy Phase 4
Completed NCT03994302 - Monitoring the Antiphospholipid Syndrome:TOXicity of Drugs (APSTOX)
Completed NCT03392311 - Efficacy and Safety of AD-MSCs Plus Calpocitriol Ointment in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Terminated NCT00090844 - Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer Phase 2
Terminated NCT00213642 - Tc-99m Renography and Cisplatin-induced Nephrotoxicity N/A